3Chopt Investment Partners LLC Invests $548,000 in Danaher Co. (NYSE:DHR)

3Chopt Investment Partners LLC acquired a new stake in shares of Danaher Co. (NYSE:DHR) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 2,190 shares of the conglomerate’s stock, valued at approximately $548,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Benjamin Edwards Inc. grew its holdings in shares of Danaher by 1.8% during the second quarter. Benjamin Edwards Inc. now owns 2,153 shares of the conglomerate’s stock worth $538,000 after purchasing an additional 38 shares during the last quarter. Patrick M Sweeney & Associates Inc. grew its holdings in Danaher by 3.4% during the 2nd quarter. Patrick M Sweeney & Associates Inc. now owns 1,230 shares of the conglomerate’s stock worth $307,000 after acquiring an additional 40 shares during the last quarter. Trust Co of Kansas increased its position in Danaher by 4.1% in the 2nd quarter. Trust Co of Kansas now owns 1,022 shares of the conglomerate’s stock valued at $255,000 after acquiring an additional 40 shares during the period. Abacus Planning Group Inc. increased its position in Danaher by 0.7% in the 2nd quarter. Abacus Planning Group Inc. now owns 5,439 shares of the conglomerate’s stock valued at $1,359,000 after acquiring an additional 40 shares during the period. Finally, Certified Advisory Corp lifted its holdings in shares of Danaher by 4.5% during the second quarter. Certified Advisory Corp now owns 926 shares of the conglomerate’s stock worth $231,000 after purchasing an additional 40 shares during the period. Institutional investors own 79.05% of the company’s stock.

Insider Activity

In other Danaher news, CEO Rainer Blair sold 9,007 shares of Danaher stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the completion of the transaction, the chief executive officer now owns 97,983 shares in the company, valued at approximately $27,435,240. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Danaher news, CEO Rainer Blair sold 9,007 shares of the firm’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the transaction, the chief executive officer now directly owns 97,983 shares in the company, valued at approximately $27,435,240. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Matthew Mcgrew sold 16,172 shares of the company’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the completion of the sale, the chief financial officer now owns 29,407 shares of the company’s stock, valued at approximately $8,229,254.88. The disclosure for this sale can be found here. Insiders sold 39,659 shares of company stock worth $11,042,433 over the last three months. 11.10% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the company. The Goldman Sachs Group increased their price objective on Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a report on Wednesday, July 24th. Leerink Partners raised their price objective on Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 24th. StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday, June 25th. Robert W. Baird increased their target price on shares of Danaher from $271.00 to $278.00 and gave the company an “outperform” rating in a research report on Wednesday, July 24th. Finally, TD Cowen boosted their price target on shares of Danaher from $290.00 to $310.00 and gave the stock a “buy” rating in a research report on Wednesday, July 24th. Seven research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to MarketBeat.com, Danaher presently has a consensus rating of “Moderate Buy” and an average price target of $278.94.

Danaher Stock Performance

Shares of DHR opened at $278.02 on Tuesday. The stock has a 50-day moving average of $270.77 and a 200-day moving average of $258.06. Danaher Co. has a one year low of $182.09 and a one year high of $281.70. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. The company has a market cap of $205.93 billion, a PE ratio of 47.12, a P/E/G ratio of 4.55 and a beta of 0.83.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, beating the consensus estimate of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The firm had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.59 billion. During the same quarter in the previous year, the company posted $2.05 earnings per share. The company’s quarterly revenue was down 2.9% on a year-over-year basis. On average, equities research analysts predict that Danaher Co. will post 7.59 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be issued a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.39%. The ex-dividend date of this dividend is Friday, September 27th. Danaher’s dividend payout ratio is currently 18.31%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.